Fig. 4.

Sirt1 was a target of miR-22 in breast cancer cells. a The predicted binding sites of sirt1 3′UTR in miR-22 sequence and the mutations in the binding region are shown. b The luciferase activity was determined by luciferase reporter assay after MCF-7 and MDA-MB-231 cells were cotransfected with luciferase constructs and miR-22 or miR-NC. qRT-PCR was employed to assess the expressions of sirt1 in MCF-7 (c) and MDA-MB-231 (d) cells transfected with miR-NC, miR-22 or anti-miR-22. *P < 0.05